Chemotherapy for pancreatic cancer.

Published on Mar 1, 2019in Presse Medicale1.388
· DOI :10.1016/J.LPM.2019.02.025
Christoph Springfeld23
Estimated H-index: 23
(Heidelberg University),
Dirk Jäger21
Estimated H-index: 21
(Heidelberg University)
+ 4 AuthorsJohn P. Neoptolemos125
Estimated H-index: 125
(Heidelberg University)
Summary Chemotherapy is an important part of multimodality pancreatic cancer treatment. After curative resection, adjuvant chemotherapy can significantly improve disease free survival and overall survival. The current standard of care is six months adjuvant chemotherapy with modified folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (mFOLFIRINOX) in patients fit enough for this protocol, otherwise six months of gemcitabine and capecitabine based on the European Study Group for Pancreatic Cancer (ESPAC)-4 study. In patients with metastatic disease, combination chemotherapy according to the FOLFIRINOX protocol or with gemcitabine plus nab-paclitaxel is an important improvement to gemcitabine monotherapy that was the standard for many years. Patients not fit for combination chemotherapy however may still benefit from gemcitabine. Patients with good performance status may benefit from second-line chemotherapy. Chemoradiation has long been used in locally advanced pancreatic cancer but is now tempered following the LAP07 study. This trial showed no difference in overall survival in those patients with stable disease after four months of gemcitabine (with or without erlotinib) randomized to either continuation of gemcitabine therapy or chemoradiation (54 Gy with capecitabine). As an alternative to radiation, other forms local therapies including radiofrequency ablation, irreversible electroporation, high-intensity focused ultrasound, microwave ablation and local anti-KRAS therapy (using siG12D-LODER) are currently under investigation. Given the systemic nature of pancreas cancer from an early stage, the success of any local approach other than complete surgical resection (with adjuvant systemic therapy) is likely to be very limited. In patients with locally advanced, irresectable cancer, chemotherapy may offer the chance for secondary resection with a survival similar to patients with primary resectable disease. Downstaging regimens need to be evaluated in prospective randomized trials in order to make firm recommendations. Selection of patient groups for specific therapy including cytotoxics is becoming a reality using assays based on drug cellular transport and metabolism, and molecular signatures. Going forward, high throughput screening of different chemotherapy agents using molecular signatures based on patients’ derived organoids holds considerable promise.
📖 Papers frequently viewed together
3,500 Citations
10.5k Citations
384 Citations
#1Thomas Hank (University Hospital Heidelberg)H-Index: 11
#2Markus W. Büchler (University Hospital Heidelberg)H-Index: 173
Last. John P. Neoptolemos (University Hospital Heidelberg)H-Index: 125
view all 3 authors...
There is increasing interest in the use of adjuvant treatment for pancreatic cancer since although postoperative mortality is much improved, median long-term survival is only on the order of 11–15 mo. Despite a proliferation of studies in advanced pancreatic cancer indicating a benefit for chemotherapy, there has only been one small randomized adjuvant trial. A combination of 5-fluorouracil, doxorubicin, and mitomycin-C demonstrated a significantly improved median survival (23 vs 11 mo in contro...
1 CitationsSource
#1Georgios Gemenetzis (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
#2Vincent P. Groot (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 16
Last. Jin He (Johns Hopkins University)H-Index: 40
view all 14 authors...
Objective:The aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes.Background:An increasing number of LAPC patients who respond favorably to neoadjuvant thera
115 CitationsSource
#1Christoph HeiningH-Index: 15
#2Peter Horak (University Hospital Heidelberg)H-Index: 21
Last. Hanno GlimmH-Index: 41
view all 39 authors...
We used whole-genome and transcriptome sequencing to identify clinically actionable genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC). Molecular characterization of 17 PDAC patients enrolled in a precision oncology program revealed gene fusions amenable to pharmacologic inhibition by small-molecule tyrosine kinase inhibitors in all patients with KRAS wild-type (KRASwt) tumors (4 of 17). These alterations included recurrent NRG1 rearrangements predicted to drive PDA...
86 CitationsSource
Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemothe...
333 CitationsSource
#1Hanbo Zhang (UM: University of Manitoba)H-Index: 1
#2Curtis KellettH-Index: 1
Last. Christina Kim (UM: University of Manitoba)H-Index: 5
view all 4 authors...
Abstract Background Advanced pancreatic cancer (APC) has a poor prognosis. Current first-line chemotherapy options include FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin), NG (nab-paclitaxel, gemcitabine), and GEM (gemcitabine) alone. The optimal second-line regimen is unclear. For patients with disease progression with FOLFIRINOX who have a good performance status, NG might be a reasonable second-line option. Patients and Methods Patients in whom APC was diagnosed from 2012 to 2016 who und...
7 CitationsSource
#1Jin-Young Jang (Seoul National University Hospital)H-Index: 54
#2Youngmin Han (Seoul National University Hospital)H-Index: 10
Last. Seong Ho Choi (SMC: Samsung Medical Center)H-Index: 28
view all 20 authors...
Objective:This study was performed to determine whether neoadjuvant treatment increases survival in patients with BRPC.Summary Background Data:Despite many promising retrospective data on the effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC), no high-level evidence e
222 CitationsSource
#1Eva VersteijneH-Index: 11
#2J.A. VogelH-Index: 4
Last. G. van TienhovenH-Index: 21
view all 10 authors...
markdownabstractBackground: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer. Methods: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intenti...
190 CitationsSource
#1G. van TienhovenH-Index: 21
#5O.R.C. BuschH-Index: 33
Last. J. de Vos-Geelen (UM: Maastricht University)H-Index: 6
view all 13 authors...
LBA4002Background: Standard of care for patients with (borderline) resectable pancreatic adenocarcinoma is resection followed by adjuvant chemotherapy. Previous studies suggest a benefit of neoadjuvant treatment. We conducted a multicenter phase III randomized controlled trial to evaluate the effect of preoperative chemoradiotherapy. Methods: Patients with (borderline) resectable pancreatic cancer, pathologically confirmed, were randomized between immediate surgery (arm A) and preoperative chemo...
118 CitationsSource
#1Thierry ConroyH-Index: 60
#2Pascal HammelH-Index: 86
Last. Jean-Baptiste BachetH-Index: 35
view all 20 authors...
LBA4001Background: FOLFIRINOX is more effective than gem as first-line treatment in metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed the benefit of mFOLFIRINOX in the adjuvant setting. Methods: PRODIGE 24/CCTG PA.6 is a phase III multicenter, randomized clinical trial. Pts aged 18-79 years with histologically proven pancreatic ductal adenocarcinomas, 21-84 days after R0 or R1 resection, WHO PS ≤1, adequate hematologic and renal function, and no ca...
89 CitationsSource
#1Alexander Drilon (Cornell University)H-Index: 57
#2Romel Somwar (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 28
Last. Gopinath Ganji (GSK: GlaxoSmithKline)H-Index: 7
view all 26 authors...
NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous adenocarcinomas (IMAs) of the lung. The oncoprotein binds ERBB3-ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic paradigm of ERBB3/ERBB2 inhibition. As proof of concept, a durable response was achieved with anti-ERBB3 monoclonal antibody therapy (GSK2849330) in an exceptional responder with an NRG1-rearranged IMA on a phase 1 trial (NCT01966445). In contrast, response was not achieved ...
81 CitationsSource
Cited By47
#1Le Blanc (Charité)
#3Ishaque (MSD: Merck & Co.)
Last. Schuth (Heidelberg University)
view all 23 authors...
Abstract null Pancreatic ductal adenocarcinoma (PDAC) is characterized by high drug resistance and poor prognosis. Novel therapeutic and stratification strategies are urgently needed. Here, we present an integration of in-depth genomic and transcriptomic characterization with drug screening and clinical outcome based on a catalogue of 51 patient-derived tumor organoids (PDOs) from resected PDAC. Known PDAC molecular subtypes and their prognostic value are conserved in organoids. Integration of t...
#1Susanne Roth (University Hospital Heidelberg)H-Index: 11
#2Thilo Hackert (University Hospital Heidelberg)H-Index: 57
Das Pankreaskarzinom ist eine sehr aggressive Krebserkrankung mit einer auserst schlechten Prognose. Das Uberleben der Patienten in samtlichen Tumorstadien ist jedoch sehr unterschiedlich. Standardtherapien, die sich uberwiegend an TNM-Klassifikation, Allgemeinzustand und Komorbiditat orientieren, sind in ihrer Effektivitat sehr variabel. Neue Technologien mit Multi-omics-Tumorcharakterisierungen haben in den letzten Jahren die molekulare Heterogenitat des Pankreaskarzinoms aufgezeigt. In der kl...
#1Mounira Chalabi-Dchar (UCBL: Claude Bernard University Lyon 1)
#2Tanguy Fenouil (UCBL: Claude Bernard University Lyon 1)H-Index: 4
Last. Jérôme Guitton (UCBL: Claude Bernard University Lyon 1)H-Index: 28
view all 0 authors...
5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat patients with solid tumours, such as colorectal and pancreatic cancers. Colorectal cancer (CRC) is the second leading cause of cancer-related death and half of patients experience tumour recurrence. Used for over 60 years, 5-FU was long thought to exert its cytotoxic effects by altering DNA metabolism. However, 5-FU mode of action is more complex than previously anticipated since 5-FU is an extrinsic source of RNA modification...
#1Jifan Chen (ZJU: Zhejiang University)H-Index: 2
#2Yuheng Bao (ZJU: Zhejiang University)H-Index: 1
Last. Jiali Luo (ZJU: Zhejiang University)
view all 16 authors...
Pancreatic cancer is a severe disease that threatens human health. The hypoxic tumor microenvironment in pancreatic cancer leads to resistance to conventional therapies and helps to maintain tumor malignancy. First-line drugs present the disadvantage of systemic side effects, and a synergistic method with sonodynamic therapy (SDT) has been established as an emerging approach. In this study, we produced hypoxia-alleviating nanoplatforms (denoted as PZGI NPs) with zeolitic imidazolate frameworks-9...
#1Lilly J Brada (UvA: University of Amsterdam)H-Index: 1
#2M.S. Walma (UvA: University of Amsterdam)H-Index: 1
Last. Sebastiaan FestenH-Index: 21
view all 25 authors...
BACKGROUND AND OBJECTIVES Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable. It remains unclear, however, which specific patients benefit from FOLFIRINOX. Two nomograms were developed predicting overall survival (OS) and resection at the start of FOLFIRINOX for LAPC. METHODS From our multicenter, prospective LAPC registry in 14 Dutch hospitals, LAPC patients sta...
1 CitationsSource
#1Liang Liang (Fudan University)H-Index: 1
#2Ying Ding (Fudan University)H-Index: 11
Last. Mengsu Zeng (Fudan University)H-Index: 28
view all 7 authors...
Background Multiple guidelines for pancreatic ductal adenocarcinoma (PDAC) suggest that all stages of patients need to receive postoperative adjuvant chemotherapy. S-1 is a recently emerged oral antitumour agent recommended by the guidelines. However, which population would benefit from S-1 needs to be determined, and predictors of chemotherapy response are needed for personalized precision medicine. This pilot study aimed to initially identify whether whole-tumour evaluation with MRI and radiom...
#1Parnia Rahnamay Farnood (KAUMS: Kashan University of Medical Sciences)
#2Romina Danesh Pazhooh (KAUMS: Kashan University of Medical Sciences)
Last. Bahman Yousefi (Tabriz University of Medical Sciences)H-Index: 35
view all 4 authors...
Abstract Pancreatic cancer (PC) is among fatal malignancies, with a dismal prognosis and a low survival rate of 5 to 10%. In both sporadic and inherited PC, gene alterations, such as BRCA1/2, PALB2, and ATM, can occur frequently. Currently, surgery, chemo- and radio-therapy are the most common therapeutic strategies for treating this cancer. DNA damage response (DDR) establishes multiple pathways that eliminate DNA damage sites to maintain genomic integrity. Various types of cancers and age-rela...
#1Katsutaka Mitachi (Tohoku University)H-Index: 2
#2Kyohei Ariake (Tohoku University)H-Index: 8
Last. Michiaki Unno (Tohoku University)H-Index: 67
view all 12 authors...
The collagen gel droplet-embedded drug sensitivity test (CD-DST) was revealed to be useful for predicting the effect of S-1 adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC). However, collection of an adequate number of PDAC cells is difficult due to the surrounding fibroblasts. Thus, the aim of this study was to discover novel biomarkers to predict chemosensitivity based on the CD-DST results. Proteomics analysis was performed using liquid chromatography tandem mass spectrometry...
Last. Valery Z. Grdzelishvili (UNCC: University of North Carolina at Charlotte)H-Index: 21
view all 3 authors...
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis and a dismal survival rate, expected to become the second leading cause of cancer-related deaths in the United States. Oncolytic virus (OV) is an anticancer approach that utilizes replication-competent viruses to preferentially infect and kill tumor cells. Vesicular stomatitis virus (VSV), one such OV, is already in several phase I clinical trials against different malignancies. VSV-based recombinant viruses ...
1 CitationsSource
#1Hans Martin Singh (Heidelberg University)H-Index: 1
#2Peter Bailey (Glas.: University of Glasgow)H-Index: 39
Last. Christoph Springfeld (Heidelberg University)H-Index: 23
view all 8 authors...
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited treatment options. Recently, the Poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib has been approved for maintenance therapy after successful platinum-based chemotherapy in patients with germline mutations in BRCA1 and BRCA2. Approval was based on the POLO study that has shown a significant improvement in progression-free survival for patients with metastatic PDAC after at least 4 months of platinum-based chemotherapy....
2 CitationsSource